bi 1467335
Small moleculeexperimental
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 7, 2016 (NCT02733627)
Timeline
Indications
Mechanism of action
- Amine oxidase, copper containingINHIBITOR
AOC3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bi 1467335
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03979820 | Phase 1 | Jul 8, 2019 | Boehringer Ingelheim |
| NCT03927209 | Phase 1 | Jun 6, 2019 | Boehringer Ingelheim |
| NCT03483506 | Phase 1 | Apr 10, 2018 | Boehringer Ingelheim |
| NCT03382509 | Phase 1 | Jan 12, 2018 | Boehringer Ingelheim |
| NCT03302091 | Phase 1 | Oct 17, 2017 | Boehringer Ingelheim |
| NCT03238963 | Phase 2 | Sep 19, 2017 | Boehringer Ingelheim |
| NCT03159455 | Phase 1 | Jun 7, 2017 | Boehringer Ingelheim |
| NCT03166735 | Phase 2 | Jun 6, 2017 | Boehringer Ingelheim |
| NCT02999191 | Phase 1 | Jan 10, 2017 | Boehringer Ingelheim |
| NCT02733627 | Phase 1 | Jul 7, 2016 | Boehringer Ingelheim |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 10 | 10 | 2 | 2016 |
1 organizations
Page 1 / 1